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Human somatic stem cells with neural differentiation potential can be valuable for developing cell-based therapies, including
treatment of birth-related defects, while avoiding issues associated with cell reprogramming. Precisely defining the “identity” and
differentiation potential of somatic stem cells from different sources, has proven difficult, given differences in sets of specific
markers, protocols used and lack of side-by-side characterization of these cells in different studies. Therefore, we set to compare
expression of mesenchymal and neural markers in human umbilical cord-derived mesenchymal stem cells (UC-MSCs), pediatric
adipose-derived stem cells (p-ADSCs) in parallel with human neural stem cells (NSCs). We show that UC-MSCs at a basal level express
mesenchymal and so-called “neural”markers, similar to thatwe previously reported for the p-ADSCs. All somatic stemcell populations
studied, independently from tissue and patient of origin, displayed a remarkably similar expression of surface markers, with the main
difference being the restricted expression of CD133 and CD34 to NSCs. Expression of certain surface and neural markers was affected
by the expansion medium used. As predicted, UC-MSCs and p-ADSCs demonstrated tri-mesenchymal lineage differentiation potential,
though p-ADSCs display superior chondrogenic differentiation capability. UC-MSCs and p-ADSCs responded also to neurogenic induction
by up-regulating neuronal markers, but crucially they appeared morphologically immature when compared with differentiated NSCs.
This highlights the need for further investigation into the use of these cells for neural therapies. Crucially, this study demonstrates the
lack of simplemeans to distinguish between different cell types and the effect of culture conditions on their phenotype, and indicates
that a more extensive set of markers should be used for somatic stem cell characterization, especially when developing therapeutic
approaches.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Abbreviations: p-ADSC, pediatric adipose tissue derived stem cells; NSC, neural stem cells; UC-MSC, umbilical cord derived stem cells
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There are several challenges to producing cell-based therapies
of the quality, safety and scale needed for clinical use. The use
of somatic stem cells offers the advantage of avoiding the issue
of tumorigenicity and costly reprogramming linked to the use of
ES and iPS (Ben-David and Benvenisty, 2011; Bianco et al.,
2013), as well as offering the possibility of using minimally
manipulated autologous stem cells and thereby preventing any
risk of rejection or Graft-versus-Host-Disease seen with the use
of allogeneic tissues and cells. Important factors to be
considered in the development of cell transplantation therapies
are availability and differentiation potential of the stem cell
type selected, and the use of allogeneic versus autologous stem
cells.
It has long been known that mesenchymal stem cells (MSCs)
are capable of differentiation along the mesenchymal lineages,
forming adipose tissue (adipocytes), cartilage (chondrocytes)
and bone (osteoblasts) (Pittenger et al., 1999, 2000). MSCs can
be isolated from a number of tissues, including but not limited
to bone marrow, adipose tissue, and, umbilical cord blood and
matrix (Pittenger, 2008; Wang et al., 2004; Zuk et al., 2001).
Bone marrow derived MSCs (BMSCs) have been the most widely
studied of the MSCs, however due to the invasive nature of their
isolation, much attention has been recently paid to other MSCs.
Umbilical cord matrix, umbilical cord blood and adipose tissue
are byproducts of certain procedures and previously thought of
as biological waste, thus preventing much of the ethical
problems associated with the use of other stem cells and
making them ideal candidates for use in stem cell therapies. We
have previously shown the high plasticity of pediatric adipose
derived-stem cells (p-ADSC) and their ability to differentiate
towards the mesenchymal and neurogenic lineages (Guasti et
al., 2012). However, it has since been reported to be easier to
isolate MSCs with a high purity from Wharton's Jelly, than from
bone marrow or adipose tissue (Liu et al., 2014), therefore
making this source extremely attractive. There is potential for
stem cells to be employed to treat childhood neurological
disorders, as well as to be used to further our understanding of
the developing nervous system and the pathological processes
that underlie these conditions. The therapeutic benefits of
MSCs have been demonstrated in animal models recapitulating
ischemic stroke, spinal cord injury and Parkinson's disease (Ding
et al., 2007; Yang et al., 2008). Despite this clinical trials have
not proved as successful (Chen et al., 2013; Dalous et al., 2012;
Mazzini et al., 2006; Prasongchean and Ferretti, 2012; Uccelli et
al., 2011).
The aim of this study was to comprehensively compare,
for the first time, pediatric p-ADSCs and UC-MSCs, charac-
terizing their marker expression and differentiation capa-
bility including their neurogenic potential alongside human
neural stem cells (NSCs). We establish, for the first time, the
similarity in surface marker expression profiles between
these three human somatic stem cell types despite their
origins. The use of animal-based products in the culturing of
cells for therapeutic purposes is undesirable (Tekkatte et
al., 2011). Here we assessed whether the use of cord blood
plasma instead of fetal calf serum may provide a simple
way of avoiding the use of animal based products in UC-MSC
cultures. In our hands although UC-MSCs had a lower
potential to differentiate towards the mesenchymallineages, both UC-MSCs and p-ADSCs demonstrated similar
upregulation of neural markers after induction, as well as
a significant change in morphology. Despite this, their
immaturity in terms of neurogenicity was apparent when
compared side-by-side with NSCs. The differences in
preferential differentiation of somatic stem cells reported
here and the medium used may have important bearing on
the use of these somatic stem cells for therapeutic
purposes.
Materials and methods
Materials
All chemicals were from Sigma-Aldrich (St Louis, USA),
unless otherwise stated.
Cell growth and differentiation
All procedures involving human tissue were carried out in
accordance to the Human Tissue Act 2006. Cells were grown
in humidified incubators at 37 °C with 5% CO2.
Human umbilical cord mesenchymal stem cells (UC-MSCs)
Whole umbilical cords were collected from consenting
mothers with healthy full-term pregnancies. Umbilical
cord mesenchymal stem cells (UC-MSC) were isolated from
the Wharton's jelly of the umbilical cord using a modified
protocol described previously by Weiss et al. (Weiss et al.,
2006) and unless stated otherwise were cultured in high
glucose Dulbecco's modified Eagle's medium with
GlutaMAX™ (DMEM; Life Technologies) and supplemented
with 10% embryonic stem cell-qualified fetal bovine serum
(ES-FBS; Invitrogen, Carlsbad, CA) and 1% penicillin/
streptomycin (Life Technologies) — termed UC-MSC–FBS.
In some experiments UC-MSC were also cultured in
umbilical cord blood low enriched plasma, supplemented
with EGF and FGF2; these cells are referred to as UC-MSC–
CP within the text. Low enriched cord plasma (CP) was
prepared by following a protocol modified from Chieregato
et al. (Chieregato et al., 2011). Briefly, CP was thawed at
37 °C to promote cell disruption. After thawing, CP was
heat inactivated at 56 °C for 30 min, centrifuged at 1000 g
for 10 min at room temperature to spin down all the
particles, and finally the CP supernatant removed and
stored at −20 °C prior to use.
Humanpediatric adipose tissue-derived stemcells (p-ADSCs)
Abdominal adipose tissue was collected from consenting
patients under ethical approval from the Camden and Islington
Community Local Research Ethics Committee (London, UK).
p-ADSCs were isolated from lipoaspirates of pediatric patients
as previously described (Guasti et al., 2012). Isolated p-ADSCs
were cultured in high glucose DMEM with GlutaMAX™ and
supplemented with 10% ES-FBS and 1% penicillin/
streptomycin.
Human neural stem cells (NSCs)
The brains from human embryos between 6 and 10 weeks
old were collected through Human Developmental Biology
Resource (HDBR) and human NSCs were isolated as
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NSCs were grown as monolayers in DMEM/F12 media with
Glutamax (Life Technologies) supplementedwith 1% penicillin/
streptomycin, 1% N2 supplement, 2% B27 supplement (both
Life Technologies), 20 ng/ml human recombinant FGF2,
20 ng/ml human recombinant EGF (both Peprotech), 50 μg/ml
BSA fraction V and 5 μg/ml heparin and 10 μg/ml laminin
(Sigma).
Adipogenic differentiation
Adipogenic differentiation was induced in confluent cells
with DMEM medium containing Glutamax, 1% penicillin/
streptomycin, 10% ES-FBS, 1 μM dexamethasone, 10 ng/ml
insulin, 500 mM 3-isobutyl-1-methylxanthine and 1 mM
rosiglitazone. After 3 weeks, cells were fixed in 10% formalin
and analyzed semi-quantitatively with Oil Red staining as
previously described (Guasti et al., 2012).
Osteogenic differentiation
Osteogenic differentiation was induced in confluent cells
with DMEM medium containing Glutamax, 1% penicillin/
streptomycin, 10% ES-FBS, 0.1 μM dexamethasone, 100 μg/ml
ascorbate and 10 mM β-glycerophosphate. After 3 weeks,
cells were fixed in ice-cold 70% ethanol and analyzed
semi-quantitatively with Alizarin Red staining as previously
described (Guasti et al., 2012).
Chondrogenic differentiation
Chondrogenic differentiation was induced in confluent cells
with DMEM medium containing Glutamax, 1% penicillin/
streptomycin, 10% ES-FBS, 0.1 μM dexamethasone, 50 μg/ml
ascorbate, 10 ng/ml transforming growth factor (TGF) β1 and
insulin, transferrin, selenium. After 3 weeks, cells were fixed
in 4% paraformaldehyde and analyzed semi-quantitatively with
Alcian Blue staining as previously described (Guasti et al.,
2012).
Neural differentiation
Neural differentiation was induced in confluent cells by
changing the expansion medium to DMEM with Glutamax
supplemented with 1% penicillin/streptomycin, 10% ES-FBS,
10 μM forskolin, 5 mM KCl, 2 mM valproic acid, 1 μm
hydrocortisone and 5 μg/ml insulin as described previously
(Huang et al., 2007). Cells were either analyzed for gene
expression after 3 weeks of differentiation or analyzed for
protein expression by immunofluorescence after 2 weeks in
this differentiation media. Neural stem cells were differen-
tiated in DMEM/F12 medium with Glutamax and same
supplements, omitting the ES-FBS to prevent the differen-
tiation towards an astrocytic phenotype. After 10 days the
medium was changed to maturation medium composed of
neurobasal medium A supplemented with 1% penicillin/
streptomycin, 1% L-glutamine and 2% B27 supplement for
another 2 weeks.
Flow cytometry
For cell surface labeling, cells were incubated in 2.5% FBS in
PBS blocking solution to prevent any non-specific protein
binding. Cells were then incubated with antibodies diluted in
blocking solution for 10 min at 4 °C followed by two washesin FACS buffer. For double labeling with intracellular
markers the cells were first fixed in 4% paraformaldehyde
(PFA) for 20 min at 4 °C in the dark. After staining with
surface markers antibodies followed by permeabilization the
cells were incubated with intracellular marker antibodies for
30 min at room temperature in dark. For negative controls
cells were incubated with the isotype control. The antibod-
ies used and their appropriate dilutions are listed in
Supplemental Table 2. BD FACSCalibur TM was used to
carry out flow cytometry analysis and data was analyzed
using FlowJo 6.4.7 software.
Immunocytochemistry
Cells were fixed in 4% PFA prior to immunocytochemical
protein detection followed by incubation with a blocking/
permeabilizing buffer (10% FBS, 3% BSA, and 0.2%
Triton-X100 in PBS). Primary and secondary antibodies
were diluted in blocking buffer as specified in Supplemental
Table 1. Incubation times were 2 h at room temperature for
primary and 1 h at RT for secondary antibodies. Hoechst
33258 (2 μg/ml, Sigma) was added during secondary anti-
body incubation to counterstain cell nuclei. Negative
controls were incubated with the secondary antibody only.
Images were acquired with an inverted microscope Olympus
IX71 (Carl Zeiss, Jena, Germany) equipped with a Hamamatsu
ORCA-ER digital camera (Hamamatsu Corp., Bridgewater,
NJ).
Histology and immunohistochemistry of the umbilical
cord
Tissue was fixed in 4% PFA prior to embedding in OCT and
cryosectioning for histological and immunohistochemical
evaluation. Sections of umbilical cord were stained with
hematoxylin and eosin (H&E). For immunohistochemical
analysis, post incubation in primary antibody overnight at
4 °C and washing 3 times with PBS, the sections were
incubated in biotinylated secondary antibody (primary and
secondary antibodies are listed in Supplemental Table 1)
for 1 h. The target antigen signal was detected with
Vectorstain Avidin–Biotin Complex kit (Vector Laboratories,
Burlingame,CA). Hematoxylin was used to counterstain cell
nuclei. Images were acquired with an Axiovert 135 (Zeiss)
with a ProgRes C14 digital camera using OpenLab software
(PerkinElmer Life).
Reverse transcription-polymerase chain reaction
(RT-PCR) and quantitative real-time polymerase
chain reaction (RT-qPCR)
RNA was extracted from cells and tissue using Tri-Reagent
(Life Technologies) according to the manufacturer's
protocol. RNA was retro-transcribed with Moloney
murine leukemia virus reverse transcriptase (Promega,
Madison, WI).
Real time quantitative polymerase chain reaction
(RT-qPCR) was preformed with ABI Prism 7500 sequence
detection system (Applied Biosystems) using the Quantitect
SYBR Green PCR kit (Qiagen, Hilden, Germany) following the
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summarized in Supplemental Table 3. Gene expression data
were normalized using GAPDH housekeeping gene as a
reference using the 2-ΔΔCt method.
Statistical analysis
Data are presented as mean ± SEM. The statistical analysis
was performed using GraphPad Prism version 5.00 for
Windows. Statistical significance was evaluated by Student's
t-test or ANOVA followed by a Bonferroni post-hoc test. A
p value equal to or less than 0.05 was considered as
statistically significant.
Results
Comparison of surface and neuralmarkers in UC-MSCs,
p-ADSCs and NSCs
All three human somatic stem cell types, UC-MSCs, p-ADSCs
and NSCs, possessed adherent properties and fibroblastic
morphology. We assessed the expression of a typical panel of
mesenchymal surface markers and neural markers in order
to establish whether they could be readily distinguished on
the basis of their surface markers and which human
mesenchymal stem cell population, p-ADSCs or UC-MSC,
shared more features with NSC. At least three cell lines from
different individuals were used unless otherwise stated.
Mesenchymal surface markers were analyzed by flow
cytometry in NSC, p-ADSC andUC-MSC (Table 1). We compared
surface markers in UC-MSCs cultured under standard condi-
tions (FBS-containing medium; UC-MSC–FBS) and human cord
plasma-containing medium (UC-MSC–CP) to assess the poten-
tial usage of the latter as a substitute for FBS and ensure that
the cellular profiles were not unfavorably changed. All cells
expressed similar high levels of the mesenchymal markers
CD29 (integrin β1), CD44 (hyaluronic acid receptor), CD73Table 1 Comparative characterization of NSC, UC-MSC and p-AD
UC-MSC–FBS
Mesenchymal markers CD13 97.48 ± 1.4
CD29 99.28 ± 0.51
CD44 98.98 ± 0.80
CD73 98.28 ± 1.01
CD90 98.95 ± 0.85
CD105 99.00
CD166 97.00 ± 1.55
Non-mesenchymal markers CD10 6.00 ± 5.80
CD14 0.57 ± 0.26
CD31 0.50 ± 0.14
CD34 1.43 ± 0.75
CD45 0.34 ± 0.12
CD117 3.69 ± 1.41
Data are percentages represented as mean ± SEM, n ≥ 3; SEM is not sh
stem cells; NSC, neural stem cells; UC-MSC, umbilical cord mesenchym
⁎ NSC vs. UC-MSC–CP p b 0.05.
⁎⁎ UC-MSC–CP vs. NSC, p-ADSC and UCSC–FBS p b 0.001.
⁎⁎⁎ NSC vs. ADSC, UC-MCS–FBS and UC-MSC–CP p b 0.0001.(ecto-5′-nucleotidase), CD90 (Thy1) and CD166 (activated
leukocyte cell adhesion molecule). NSCs tended to have a
lower expression of CD105 (endoglin) compared to the other
stem cell types, although only two separate NSCs isolates were
analyzed for this marker. All cells expressed similar low levels
of the negative markers CD14 (monocyte differentiation
antigen), CD31 (platelet endothelial cell adhesion
molecule-1), CD45 (lymphocyte common antigen) and CD117
(c-kit). High expression of CD10 (neprilysin) was noted in
UC-MSCs cultured in CP (p b 0.001 vs. NSC, p-ADSC and
UC-MSC–FBS); CD10 is a metallopeptidase typically expressed
by hematopoietic progenitors with the capacity to differenti-
ate into T, B or Natural Killer cells (Galy et al., 1995). NSCs
were the only stem cell type with high expression of CD34
(hematopoietic progenitor cell antigen; p b 0.0001 vs.
p-ADSC, UC-MSC–FBS and UC-MSC–CP); this was the main
notable difference between NSCs and the mesenchymal stem
cells in mesenchymal marker expression.
The expression of proteins normally associated with the
neural lineage was assessed in UC-MSC–FBS, UC-MSC–CP and
NSC by flow cytometry (Fig. 1, Table 2) as neurogenic markers
in p-ADSCs had been previously characterized (Guasti et al.,
2012). NSCs were taken as the positive control and used as a
reference for the statistical analysis. The markers of neural
stem/progenitor cells, Sox2, nestin, and vimentin, that are
expressed early in development of the central nervous system,
and prominin (CD133), amarker of neurogenic radial glia, were
highly expressed in NSC, as expected. CD133, while found in
75% NSCs, was hardly detectable in UC-MSCs, independently
from the culture conditions used (p b 0.0001). In contrast,
vimentin was more highly expressed in UC-MSC–CP than
UC-MSC–FBS (p b 0.05), with expression levels similar
to those detected in NSCs (99%). No statistically sig-
nificant difference was observed in the percentage of
nestin-expressing cells among the different cultures. Expres-
sion of SOX2 was much lower in UC-MSCs than in NSCs
(p b 0.0001); surprisingly, however, the UC-MSCs cultured in
CP expressed higher levels of SOX2 protein compared to thoseSC using flow cytometry.
UC-MSC–CP p-ADSC NSC
99.93 ± 0.06 97.43 ± 2.16 82.07 ± 9.53 ⁎
99.97 ± 0.03 98.70 ± 1.15 99.90 ± 0.10
99.95 ± 0.05 99.87 ± 0.03 99.83 ± 0.06
99.93 ± 0.06 99.17 ± 0.68 99.47 ± 0.33
99.95 ± 0.05 99.07 ± 0.23 67.13 ± 24.65
98.28 ± 0.66 92.43 ± 6.18 57.20
99.67 ± 0.31 92.30 ± 6.45 99.50 ± 0.15
82.32 ± 14.85 ⁎⁎ 6.17 ± 2.4 0.18 ± 0.10
0.34 ± 0.21 0.52 ± 0.21 0.19 ± 0.15
2.17 ± 1.90 0.49 ± 0.30 4.94 ± 4.77
0.86 ± 0.22 2.42 ± 2.33 94.10 ± 2.04 ⁎⁎⁎
0.53 ± 0.12 0.58 ± 0.24 0.51 ± 0.17
1.26 ± 0.87 1.07 ± 0.18 10.0 ± 7.75
own when n b 3. Abbreviations: p-ADSC, pediatric adipose-derived
al stem cells; CP, cord plasma; FBS, fetal calf serum.
Figure 1 Comparative characterization of neural stem cell markers expressed by human UC-MSC (UCMSC) and p-ADSC (ADSC).
Neural stem cell marker expression as detected by flow cytometry: CD133, vimentin, nestin and SOX2 protein expression of NSC,
UC-MSC–FBS, and UC-MSC–CPs. Histograms/plots: gray line(−)/plots = negative control; black line(−)/plots = sample. Dot plot gate:
positive/negative threshold. Shown one representative out of ≥3 independent experiments. Number = % of cells represented as
mean ± SEM. Graphs show statistic comparison of protein expression between populations. *p b 0.05; **p b 0.001. Abbreviations:
UC-MSC, umbilical cord mesenchymal stem cells; FBS, fetal bovine serum; CP, cord plasma; NSC, neural stem cells.
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SOX2-positive UC-MSC–CB (48%) was not as high as in NSCs
(98%). As SOX2 is expressed also in pluripotent human
embryonic stem (ES) cells, we wished to establish whether
expression of SOX2 in UC-MSC–CB might be associated with a
reversal to pluripotency rather than reflecting neural poten-
tial. Analysis of the expression of the ES cell markers, SSEA-1,
SSEA-4, and OCT3/4, by flow cytometry showed that SSEA-1
was not expressed in UC-MSC–CPs, and that less than 6% of
cells expressed SSEA-4, and OCT3/4 (Fig. 2). Analysis of OCT4
by RT-PCR confirmed lack of expression of this pluripotency
transcription factor. This suggests that up-regulation of SOX2 is
not associate with an ES-like phenotype.To further confirm this, we assessed expression of addi-
tional neural markers that had been detected in p-ADSCs
(Guasti et al., 2012). As shown by flow cytometry, surprisingly,
the neuronal marker, ß3-tubulin, was similarly expressed in
UC-MSC-CPs and NSCs. In contrast, low to nil expression of
GFAP, amarker of neurogenic radial glia detected in 66% of the
NSCs, was observed in the UC-MSCs independently of the
culture conditions used. The oligodendrocyte progenitor
marker, O4, was not detected in any of the cell lines, but
PDGFRα, that has been associated with motility of mesenchy-
mal stem cells, as well as being a very early oligodendrocyte
precursor marker, was expressed in high percentage of cells
(77%) only in the UC-MSC–CP cultures. The late neural markers
Table 2 Comparative characterization of neural
lineage-associated markers expressed by NSC and UC-MSC
using flow cytometry.
NSC UC-MSC–FBS UC-MSC–CP
GFAP 66.40 ± 3.85 † 2.03 ± 0.93 1.63 ± 0.64
PDGFRα 0.70 ± 0.41 †† 2.88 77.32 ± 11.30
O4 0.38 ± 0.24 0.96 ± 0.58 0.18 ± 0.04
P75NGFR 12.46 ± 4.46 ‡ 1.34 ± 0.92 0.76 ± 0.15
β3-Tubulin 99.50 92.87 ± 3.93 95.30 ± 0.42
Data are percentages represented as mean ± SEM, n ≥ 3, if no
SEM is indicated only two isolates were analyzed (n = 2).
Abbreviations: UC-MSC, umbilical cord mesenchymal stem cells;
FBS, fetal bovine serum; CP, cord plasma; NSC, neural stem
cells, N/P, non-performed.
† NSC vs. UC-MSC–FBS and UC-MSC–CP p b 0.0001.
‡ NSC vs. UC-MSC–FBS and UC-MSC–CP p b 0.001.
†† NSC vs. UC-MSC–CP p b 0.05.
Figure 2 Pluripotency marker expression as detected by flow
expression in UC-MSC-CPs. Histograms/plots: gray line(−)/plots =
positive/negative threshold. Shown one representative out of ≥3
mean ± SEM. Graphs show statistic comparison of protein expression
SOX2 gene expression in UC-MSC−FBS, UC-MSC−CP and NSC in co
GAPDH. Abbreviations: UC-MSC, umbilical cord mesenchymal stem c
cells.
6 S.E.P. New et al.P75 NGFR (CD271), recently identified also in human neural
progenitors in the adult subventricular zone, was hardly
detectable in UC-MSC–CPs, and present only in a small subset
of NSCs (12%).
To assess cellular localization of neural markers detected
in UC-MCS by flow cytometry, and establish whether
expression of such markers in UC-MSCs might reflect the
existence of a sub-population of cell in the Wharton's jelly
(Fig. 3A) from which they were derived, we carried
immnocytochemistry experiments, UC-MSCs, like the
Wharton's jelly in cord sections, expressed vimentin, and
approximately 50% of the cells in culture were smooth
muscle alpha actin (αSMA)-positive (Figs. 3B–E). In contrast,
neural markers expressed by UC-MSCs, including nestin,
GFAP, β3-tubulin (Figs. 3F–H) and NF-200 (not shown) were
not detected in the Wharton's jelly (not shown). The
expression of the cytoskeletal neural markers, GFAP,
β3-tubulin and NF-200, was non-filamentous in the
UC-MSCs. In addition, low levels of SOX2 expression were
observed in UC-MSC cytoplasm, but not in the umbilical cord
sections (not shown). No reactivity was noted in negative
controls (Fig. 3I).cytometry and RT-PCR: SSEA-4, SSEA1, and OCT3/4 protein
negative control; black line(−)/plots = sample. Dot plot gate:
independent experiments. Number = % of cells represented as
between populations. *p b 0.05; **p b 0.001. CD133, OCT4 and
mparison with the gene expression of the housekeeping gene,
ells; FBS, fetal bovine serum; CP, cord plasma; NSC, neural stem
Figure 3 Protein expression in human umbilical cord sections and in human umbilical cord-derived mesenchymal cells (UC-MSC)
assessed by immunochemistry (green). A–C) Human umbilical cord cross sections stained with hematoxylin and eosin (A), and by
immunohistochemistry for vimentin (B) and αSMA (C) shown at high magnification in the inset (C′). D–I) Expression of mesenchymal
and neural proteins in UC-MSC detected by immunocytochemistry: vimentin (D), αSMA (E), nestin (F), GFAP (G) and βIII-tubulin (H);
negative control where the primary antibody was omitted (I). Nuclei are visualized with Hoechst 33258 (blue). Scale bars = 100 μm.
Abbreviations: H&E, hematoxylin and eosin; αSMA, alpha smooth muscle actin; GFAP, glial fibrillary acidic protein.
Figure 4 Comparison of the tri-lineage differentiation potential of UC-MSC and p-ADSC. A) Quantification of adipogenesis (oil Red O
quantification). C) Quantification of chondrogenesis (alcian blue quantification). D) Quantification of osteogenesis (Alizarin Red
quantification). E) Data are expressed as fold changes, taking untreated p-ADSC controls as 1; *p b 0.05, **p b 0.01, ***p b 0.001.
Abbreviations: p-ADSC, pediatric adipose-derived stem cells; UC-MSC, umbilical cord mesenchymal stem cells.
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Figure 5 Neurogenic potential of UC-MSC and p-ADSC. RT-qPCR analysis of neural differentiation markers in cells maintained either
in control or neurogenic medium, including the early neural stem cell marker, SOX2, the neuronal markers, NSE and EAG1, and the
glial markers, GFAP and p0. Data are expressed as fold changes, taking untreated p-ADSC controls as 1. Abbreviations: UC-MSC,
umbilical cord mesenchymal stem cells; p-ADSC, pediatric adipose-derived stem cells; NSE, neuron-specific enolase, EAG1,
ether-à-go-go; p0, myelin protein zero; GFAP, glial fibrillary acidic protein.
8 S.E.P. New et al.Differentiation potential of UC-MSCs and p-ADSCs
The plasticity of UC-MSCs and p-ADSCs was compared by
assessing their potential to differentiate towards mesenchy-
mal lineages (chondrogenic, adipogenic and osteogenic)
when cultured in the same medium. Three independent
cell lines were used for all experiments. Both UC-MSCs and
p-ADSCs could differentiate towards the three mesenchymal
lineages as indicated by semi-quantitative analysis of oilFigure 6 NSC, UC-MSC and p-ADSC neuronal differentiation poten
(control) and differentiated NSC, UC-MSC and p-ADSC as detected by
visualized with Hoechst 33258 (blue). (B–I) Scale bars = 100 μm.
mesenchymal stem cells; p-ADSC, pediatric adipose-derived stem
microtubule-associated protein 2.red, alcian blue and alizarin red staining to detect
adipogenic, chondrogenic and osteogenic differentiation,
respectively (Fig. 4). UC-MSCs less readily underwent
adipogenic and chondrogenic differentiation when com-
pared to the p-ADSCs (p b 0.01 and p b 0.05 respectively).
The extent of osteogenic differentiation was comparable in
both UC-MSCs and p-ADSCs; a statistically significant
difference was noted when compared to the controls
(p b 0.01).tial. Protein expression of neuronal markers in undifferentiated
immunofluorescence. Positive expression in green and nuclei are
Abbreviations: NSC, neural stem cells, UC-MSC, umbilical cord
cells; TuJ1, βIII-tubulin, NF200, neurofilament-200; MAP2,
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10 S.E.P. New et al.Following exposure of p-ADSCs and UC-MSCs to neuro-
genic induction media (Fig. 5), a general trend in
up-regulation of neural markers was noted in both p-ADSCs
and UC-MSCs, although variability between individual
lines of each cell type was noted (three were analyzed per
cell type). SOX2 transcript was up-regulated to a larger
extent in UC-MSCs than p-ADSCs. Neuronal marker tran-
scripts, the neuron-specific enolase (NSE) and the
voltage-gated potassium channel EAG1 (ether a-go-go-1),
were increased in both p-ADSCs and UC-MSCs. There was
little increase in mRNAs encoding for glial markers, such as
glial fibrillary acidic protein (GFAP), and the Schwann cell
marker, P0, in both cell types. Up-regulation of neuronal
markers at the transcriptional level in UC-MSCs and
p-ADSCs, supports their potential to differentiate towards
both lineages.
We then further investigated the neurogenic potential of
these cells and evidence of differentiation at the morpho-
logical and protein level. Protein expression of the neuronal
markers, NF-200 and βIII-tubulin, was assessed by immuno-
cytochemistry in UC-MSCs and p-ADSCs differentiated in
parallel, and compared to NSCs differentiated using the
same forskolin-containing induction media (Fig. 6). The
morphology of both mesenchymal stem cells was dramati-
cally changed after two weeks in neurogenic induction
media, with differentiated p-ADSCs forming spindly net-
works unlike that of the control p-ADSCs and closer to that
of the differentiated NSCs. The non-induced UC-MSC
expressed neuronal markers on a basal level, similar to
that shown previously for p-ADSCs (Guasti et al., 2012).
However some increase in NF-200 and βIII-tubulin expres-
sion was noted in UC-MSCs and p-ADSCs cultured in the
neuronal differentiation medium. Low levels of MAP2
expression were detected in differentiated p-ADSCs, but
not in controls nor in differentiated UC-MSCs. The differen-
tiated NSC positive controls highly expressed all three
neuronal markers.Discussion
To the best of our knowledge, this is the first study to
compare in parallel a set of surface markers in the human
somatic stem cells, p-ADSCs and UC-MSCs, with NSCs. The
prototypical feature of MSCs is said to be their expression
of a defined set of surface markers including CD73, CD90
and CD105 (Kim et al., 2013). The MSCs analyzed here,
despite having been isolated from different tissues and
displaying some variations in their differentiation
potential, did not exhibit any discernible difference in
their surface marker expression, consistent with other
reports (Wagner et al., 2005; Hu et al., 2013). However,
as shown by this study, NSCs also display these surface
markers, as well as other so-called mesenchymal markers.
On the other hand, the mesenchymal stem cells studied
here were shown to express “neural” markers. This
highlights the challenge of distinguishing between cell
types and may explain discrepancy in results from
different laboratories. Crucially, it raises important issues
concerning the minimal number and combination of markers
required for accurate phenotyping of somatic progenitor/
stem cells.Neural markers are expressed in human mesenchymal
stem cells and non-neural markers in neural stem
cellsConstitutive expression of neural markers has been previ-
ously reported in p-ADSCs by us and in human bone
marrow-derived MSC by other groups (Tondreau et al.,
2004). A subset of nestin-positive cells has also been
observed in UC-MSCs (Weiss et al., 2006), but their
percentage (23%) was much lower than in our cultures
(between 92 and 100% in both growth media used). The
presence of nestin-positive cells in UC-MSC cultures could be
taken to reflect selection in vitro of perivascular cells akin to
those described in the bone marrow stem cell niche
(Mendez-Ferrer et al., 2010; Pacini and Petrini, 2014). This
interpretation, however, is not supported by analysis of
umbilical cord sections, where no evidence of nestin
expression was noted. Furthermore, there was no immuno-
reactivity for βIII-tubulin in the umbilical cord, though this
protein was found to be expressed by the UC-MSCs using both
FACS analysis and immunofluorescence; βIII-tubulin cellular
organization in these cells, however, was not as filamentous
as in neurones. Notwithstanding βIII-tubulin being defined
as a neuronal marker, its expression in human mesenchymal
cultures has also been reported in human p-ADSCs by us and
in bone marrow-derived MSCs by others (Guasti et al., 2012;
Tondreau et al., 2004). Given that in human tissue sections,
βIII-tubulin staining appears to be neural-specific and is not
found in mesenchymal tissues, it has to be concluded that
βIII-tubulin neural-specificity in humans is context depen-
dent, and its expression is induced in human cells with
progenitor/stem cell potential when grown in vitro. To our
knowledge, there are no reports of this protein being
expressed in vitro in a range of somatic stem cells in other
species. The significance of this difference is not currently
clear, but this is bound to change as differences as well as
similarity between mouse and human cells gradually become
better understood (Carninci, 2014).
Together, it seems unlikely that the in vitro conditions
select for a small subset of isolated UC-MSCs that possess a
neural phenotype; our results rather suggest that differences
in culture conditions induce changes in cell phenotype that
may reflect their intrinsic plasticity and potential to be
induced along different lineages. This is supported also by
differences in expression of SOX2, PDGFR and CD10 in
UC-MSCs grown in different media. CD10 expression is indeed
known to vary between MSCs isolated from different sources
and appears to be dependent on serum or growth factors
used (Mariotti et al., 2008).
The only surface markers we found to be differentially
expressed between mesenchymal and NSCs were CD133 and
CD34, that were detected only in the latter. Expression of
CD133 in NSCs was expected, having been observed in neural
stem cells in both human and mouse; however it should be
noted that other stem cell types, including endothelial,
hepatic and hematopoietic stem/progenitor cells, express
CD133 (Bhatia, 2001; Reubinoff et al., 2001; Schmelzer et
al., 2006; Sousa et al., 2014; Urbich and Dimmeler, 2004). In
contrast, we were surprised that the majority of NSCs
expressed CD34, widely accepted to be a hematopoietic
stem cell marker, but with as yet poorly defined function.
11A matter of identity – phenotype and differentiation potential of human somatic stem cellsCells positive for CD34 have been detected also in
embryoid-like bodies (Reubinoff et al., 2001) and a member
of the CD34 family is widely expressed in the developing
mouse brain (Nielsen and McNagny, 2008; Vitureira et al.,
2005; Nowakowski et al., 2010). Whether expression of CD34
reflects a yet unknown role of this membrane protein in NSCs,
or a leaky and/or plastic phenotype of these cells that
become apparent in culture remains to be established.
Comparison of hNSC subpopulation growth anddifferentiation
potential will help to address some of these issues.
Our study clearly shows that expansion media represent
a significant variable when phenotyping cells. In our
experiments we used the same ES-qualified serum to
expand p-ADSCs and UC-MSCs from different individuals for
direct comparison of their properties and differentiation
potential. However, we used a single CP, a platelet-poor
human cord plasma supplemented with growth factors to
speed their otherwise slow expansion rate, as the aim was
to assess whether UC-MSCs from different cords responded
similarly to the human medium. While our results demon-
strated that UC-MSCs could be effectively expanded in CP,
it is not clear at this stage whether different CBs will
differently affect gene expression and differentiation
potential of UC-MSCs. Hence, while the use of human
serum would in principle simplify taking any future stem
cell therapy from bench to bedside (Spees et al., 2004), it
may also increase variability in UC-MSC behavior. More
studies are needed to clarify the benefits and limits of this
xenogeneic-free serum and its role during expansion–
differentiation protocols as compared to well characterized
and standardized fetal bovine sera.UC-MSCs have more limited differentiation potential
than pediatric ADSCs
We have shown here that p-ADSC more readily differenti-
ated towards the chondrogenic and adipogenic lineages
than UC-MSCs, whereas a similar osteogenic potential was
noted for both types of cells. This is consistent with the
findings by Hu et al. who compared adult ADSCs and
UC-MSCs, and supports the use of p-ADSCs for skeletal
tissue engineering in young patients and in particular for
cartilage reconstruction.
We performed side-by-side experiments with p-ADSC to
compare the neurogenic potential of these mesenchymal
cell types in parallel. A general trend was noted in our
study, in which an increase in neuronal-specific transcripts
was seen for both p-ADSCs and UC-MSCs to a similar extent
when placed in a forskolin-containing media, demonstrat-
ing the capacity/potential of these cells to acquire
phenotypic characteristics not only of mesenchymal but
also of neuronally differentiated cells. This is consistent
with various reports noting the potential of UC-MSC to
differentiate towards neural lineages (Dalous et al., 2013;
Divya et al., 2012); nonetheless, differences between cell
lines and individual samples were apparent, which may
account for the variability in results/conflicting results
seen between different studies. Despite the similarities at
a basal level in neural gene expression between the two
mesenchymal cell types, p-ADSCs appear to respond more
to the neuronal differentiation medium used here in regardto morphological changes, that suggested acquisition of
neurone-like bipolar morphology, as well as to
up-regulation of neuronal transcripts and proteins. Some
expression of MAP2 was noted only in induced p-ADSCs.
However, it should be stressed that refinement of the
differentiation protocols or additional steps in the protocol
will be needed to obtain bona fide mature functional
neurones from either of these mesenchymal cell types.
Definitive evidence of neural trans-differentiation requires
assessment of neurological properties such as neuronal
polarity, synapse formation, and electrophysiological char-
acterization (Croft and Przyborski, 2006). Although several
encouraging studies have produced electrophysiological
data as well as appropriate gene transcript up-regulation
from neuronally-differentiated ADSC (Ashjian et al., 2003;
Anghileri et al., 2008; Jang et al., 2010), as yet no study
has been able to demonstrate the trans-differentiation of
these cells into a mature fully-functional neurone. This may
prove difficult without recurring to gene manipulations;
however the benefit of being able to use non-genetically
modified autologous somatic cells, instead of allogeneic
cells or iPS-derived cells, makes it important to strive
towards this goal.Conclusions
The differences in terms of markers and differentiation
potential between somatic stem cell types – be it hemato-
poietic, mesenchymal or neural – appears to be narrowing
with our ever expanding knowledge, emphasizing the need
to develop better means of distinguishing between the
different classes. The lack of surface marker combinations
highly specific to each cell type and the effect of expansion
media on the phenotype is of particular concern and needs
to be resolved, in particular for development of cell-
based therapies and appropriate interpretation of in vivo
outcomes.
Direct comparison of UC-MSCs and p-ADSCs has shown
that UC-MSCs have a more limited differentiation potential
along multiple lineages, indicating that p-ADSCs will provide
a more suitable cell source particularly for autologous
cartilage reconstruction in children.
Finally, while this study has provided encouraging data
on the neurogenic potential of the human somatic cells
studied after only a few weeks of differentiation, it is
important to note that much additional work is needed to
establish whether a more mature neural phenotype from
either of the mesenchymal stem cell population studied
here can be induced without genetic manipulations.Authors' contribution
SN designed and performed experiments, analyzed data
and wrote the manuscript; CAG and BV designed and
performed experiments, analyzed data and contributed
to the writing; AM, SG and NWB provided reagents, tissues
and critical reading of the manuscript; PF planned
research, analyzed data, obtained funding, and wrote the
manuscript.
12 S.E.P. New et al.Acknowledgments
This work was supported by grants from the Newlife
Foundation (grant 12-13/20), the Great Ormond Street
Hospital Children's Charity (grant V1234), the Antony Nolan
Trust, and a studentship to CAG from Consejo Nacional de
Ciencia y Tecnología (CONACyT, grant 210924) and Instituto
Jaliscience de la Juventud (IJJ, grant FOLIO 150); Mexico.
The human embryonic and fetal material was provided by
the Human Developmental Biology Resource (http://hdbr.
org) jointly funded by the Medical Research Council (grant
G070089) and The Wellcome Trust (grant GR082557).
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2015.04.003.References
Anghileri, E., Marconi, S., Pignatelli, A., et al., 2008. Neuronal
differentiation potential of human adipose-derived mesenchy-
mal stem cells. Stem Cells Dev. 17 (5), 909–916.
Ashjian, P.H., Elbarbary, A.S., Edmonds, B., et al., 2003. In vitro
differentiation of human processed lipoaspirate cells into early
neural progenitors. Plast. Reconstr. Surg. 111 (6), 1922–1931.
Ben-David, U., Benvenisty, N., 2011. The tumorigenicity of human
embryonic and induced pluripotent stem cells. Nat. Rev. Cancer
11 (4), 268–277.
Bhatia, M., 2001. AC133 expression in human stem cells. Leukemia
15 (11), 1685–1688.
Bianco, P., Cao, X., Frenette, P.S., et al., 2013. The meaning, the
sense and the significance: translating the science of mesenchy-
mal stem cells into medicine. Nat. Med. 19 (1), 35–42.
Carninci, P., 2014. Genomics: mice in the ENCODE spotlight. Nature
515 (7527), 346–347.
Chen, G., Wang, Y., Xu, Z., et al., 2013. Neural stem cell-like
cells derived from autologous bone mesenchymal stem cells for
the treatment of patients with cerebral palsy. J. Transl. Med.
11, 21.
Chieregato, K., Castegnaro, S., Madeo, D., et al., 2011. Epidermal
growth factor, basic fibroblast growth factor and platelet-derived
growth factor-bb can substitute for fetal bovine serum and
compete with human platelet-rich plasma in the ex vivo expansion
of mesenchymal stromal cells derived from adipose tissue.
Cytotherapy 13 (8), 933–943.
Croft, A.P., Przyborski, S.A., 2006. Formation of neurons by non-
neural adult stem cells: potential mechanism implicates an
artifact of growth in culture. Stem Cells 24 (8), 1841–1851.
Dalous, J., Larghero, J., Baud, O., 2012. Transplantation of
umbilical cord-derived mesenchymal stem cells as a novel
strategy to protect the central nervous system: technical
aspects, preclinical studies, and clinical perspectives. Pediatr.
Res. 71 (4 Pt 2), 482–490.
Dalous, J., Pansiot, J., Pham, H., et al., 2013. Use of human
umbilical cord blood mononuclear cells to prevent perinatal
brain injury: a preclinical study. Stem Cells Dev. 22 (1),
169–179.
Ding, D.C., Shyu, W.C., Chiang, M.F., et al., 2007. Enhancement of
neuroplasticity through upregulation of beta1-integrin in human
umbilical cord-derived stromal cell implanted stroke model.
Neurobiol. Dis. 27 (3), 339–353.
Divya, M.S., Roshin, G.E., Divya, T.S., et al., 2012. Umbilical cord
blood-derived mesenchymal stem cells consist of a uniquepopulation of progenitors co-expressing mesenchymal stem cell
and neuronal markers capable of instantaneous neuronal
differentiation. Stem Cell Res. Ther. 3 (6), 57.
Galy, A., Travis, M., Cen, D., et al., 1995. Human T, B, natural
killer, and dendritic cells arise from a common bone marrow
progenitor cell subset. Immunity 3 (4), 459–473.
Guasti, L., Prasongchean, W., Kleftouris, G., et al., 2012. High
plasticity of pediatric adipose tissue-derived stem cells: too
much for selective skeletogenic differentiation? Stem Cells
Transl. Med. 1 (5), 384–395.
Hu, L., Hu, J., Zhao, J., et al., 2013. Side-by-side comparison of the
biological characteristics of human umbilical cord and adipose
tissue-derived mesenchymal stem cells. Biomed. Res. Int. 2013,
438243.
Huang, T., He, D., Kleiner, G., et al., 2007. Neuron-like differen-
tiation of adipose-derived stem cells from infant piglets in vitro.
J. Spinal Cord Med. 30 (Suppl. 1), S35–S40.
Jang, S., Cho, H.H., Cho, Y.B., Park, J.S., Jeong, H.S., 2010.
Functional neural differentiation of human adipose tissue-derived
stem cells using bFGF and forskolin. BMC Cell Biol. 11, 25.
Kim, D.W., Staples, M., Shinozuka, K., et al., 2013. Wharton's jelly-
derived mesenchymal stem cells: phenotypic characterization
and optimizing their therapeutic potential for clinical applica-
tions. Int. J. Mol. Sci. 14 (6), 11692–11712.
Liu, S., Hou, K.D., Yuan, M., et al., 2014. Characteristics of
mesenchymal stem cells derived from Wharton's jelly of human
umbilical cord and for fabrication of non-scaffold tissue-
engineered cartilage. J. Biosci. Bioeng. 117 (2), 229–235.
Mariotti, E., Mirabelli, P., Abate, G., et al., 2008. Comparative
characteristics of mesenchymal stem cells from human bone
marrow and placenta: CD10, CD49d, and CD56 make a differ-
ence. Stem Cells Dev. 17 (6), 1039–1041.
Mazzini, L., Mareschi, K., Ferrero, I., et al., 2006. Autologous
mesenchymal stem cells: clinical applications in amyotrophic
lateral sclerosis. Neurol. Res. 28 (5), 523–526.
Mendez-Ferrer, S., Michurina, T.V., Ferraro, F., et al., 2010.
Mesenchymal and haematopoietic stem cells form a unique
bone marrow niche. Nature 466 (7308), 829–834.
Nielsen, J.S., McNagny, K.M., 2008. Novel functions of the CD34
family. J. Cell Sci. 121 (Pt 22), 3683–3692.
Nowakowski, A., Alonso-Martin, S., Gonzalez-Manchon, C., et al., 2010.
Ventricular enlargement associated with the panneural ablation of
the podocalyxin gene. Mol. Cell. Neurosci. 43 (1), 90–97.
Pacini, S., Petrini, I., 2014. Are MSCs angiogenic cells? New insights
on human nestin-positive bone marrow-derived multipotent
cells. Front. Cell Dev. Biol. 2, 20.
Pittenger, M.F., 2008. Mesenchymal stem cells from adult bone
marrow. Methods Mol. Biol. 449, 27–44.
Pittenger, M.F., Mackay, A.M., Beck, S.C., et al., 1999. Multilineage
potential of adult human mesenchymal stem cells. Science 284
(5411), 143–147.
Pittenger, M.F., Mosca, J.D., McIntosh, K.R., 2000. Human mesen-
chymal stem cells: progenitor cells for cartilage, bone, fat and
stroma. Curr. Top. Microbiol. Immunol. 251, 3–11.
Prasongchean, W., Ferretti, P., 2012. Autologous stem cells for
personalised medicine. New Biotechnol. 29 (6), 641–650.
Reubinoff, B.E., Itsykson, P., Turetsky, T., et al., 2001. Neural
progenitors from human embryonic stem cells. Nat. Biotechnol.
19 (12), 1134–1140.
Schmelzer, E., Wauthier, E., Reid, L.M., 2006. The phenotypes of
pluripotent human hepatic progenitors. Stem Cells 24 (8),
1852–1858.
Sousa, B.R., Parreira, R.C., Fonseca, E.A., et al., 2014. Human adult
stem cells from diverse origins: an overview from
multiparametric immunophenotyping to clinical applications.
Cytometry A 85 (1), 43–77.
Spees, J.L., Gregory, C.A., Singh, H., et al., 2004. Internalized
antigens must be removed to prepare hypoimmunogenic
13A matter of identity – phenotype and differentiation potential of human somatic stem cellsmesenchymal stem cells for cell and gene therapy. Mol. Ther. 9
(5), 747–756.
Sun, Y., Pollard, S., Conti, L., et al., 2008. Long-term tripotent
differentiation capacity of human neural stem (NS) cells in
adherent culture. Mol. Cell Neurosci. 38 (2), 245–258.
Tekkatte, C., Gunasingh, G.P., Cherian, K.M., et al., 2011.
“Humanized” stem cell culture techniques: the animal serum
controversy. Stem Cells Int. 2011, 504723.
Tondreau, T., Lagneaux, L., Dejeneffe, M., et al., 2004. Bone
marrow-derived mesenchymal stem cells already express specif-
ic neural proteins before any differentiation. Differentiation 72
(7), 319–326.
Uccelli, A., Laroni, A., Freedman, M.S., 2011. Mesenchymal stem
cells for the treatment of multiple sclerosis and other neurolog-
ical diseases. Lancet Neurol. 10 (7), 649–656.
Urbich, C., Dimmeler, S., 2004. Endothelial progenitor cells
functional characterization. Trends Cardiovasc. Med. 14 (8),
318–322.
Vitureira, N., McNagny, K., Soriano, E., et al., 2005. Pattern of
expression of the podocalyxin gene in the mouse brain during
development. Gene Expr. Patterns 5 (3), 349–354.Wagner, W., Wein, F., Seckinger, A., et al., 2005. Comparative
characteristics of mesenchymal stem cells from human bone
marrow, adipose tissue, and umbilical cord blood. Exp. Hematol.
33, 1402–1416.
Wang, H.S., Hung, S.C., Peng, S.T., et al., 2004. Mesenchymal stem
cells in the Wharton's jelly of the human umbilical cord. Stem
Cells 22 (7), 1330–1337.
Weiss, M.L., Medicetty, S., Bledsoe, A.R., et al., 2006. Human
umbilical cord matrix stem cells: preliminary characterization
and effect of transplantation in a rodent model of Parkinson's
disease. Stem Cells 24 (3), 781–792.
Yang, C.C., Shih, Y.H., Ko, M.H., et al., 2008. Transplantation of
human umbilical mesenchymal stem cells from Wharton's jelly
after complete transection of the rat spinal cord. PLoS One 3
(10), e3336.
Zuk, P.A., Zhu, M., Mizuno, H., et al., 2001. Multilineage cells from
human adipose tissue: implications for cell-based therapies.
Tissue Eng. 7 (2), 211–228.
